Year implemented: 1996
Description: This is a grant program intended to provide state and local governments with funds to improve their ability to address SUD treatment in carceral institutions. Each state that applies gets the same base amount as well as a share of money proportionate to the number of incarcerated individuals in the state.
Intended goal: Improve recovery outcomes and quality of life for incarcerated and formally incarcerated individuals suffering from SUD.
Applicable states: In the year 2023 the only states that did not apply for and receive RSAT funds were ME, NE, NJ, & SD.
Year implemented: 2022
Description: The MAT Act was part of a bill signed into law by President Biden. It removed an existing requirement that practitioners have a special waiver to legally prescribe MOUDs such as buprenorphine.
Intended goal: Obtaining the waiver involved a unique and lengthy application process. In addition, it set limits on the number of patients practitioners could prescribe medication to. The goal of the act was the remove both prescribing barriers and to increase the accessibility of MOUDs for individuals with OUD.
Applicable states: All
Year implemented: 2023
Description: In 2023 The Centers for Medicare & Medicaid Services (CMS) issued guidance to states to better design demonstration projects that improve the transition of healthcare for incarcerated individuals as they leave prison. Approved reentry demonstration requests allow states to provide services for incarcerated individuals that would not be covered by Medicaid for up to 90 days before their expected release.
Intended goal: To improve the continuity of healthcare for incarcerated individuals as they transition to non-institutional life.
Applicable states: As of 2024
1) States with approved 1115 Reentry Demonstration Requests: WA, CA, KY, IL, OR, UT & VT.
2) States with pending requests: NY, VT, NH, MA, RI, NJ, WV, NM, AZ, & MT.